Vascular Biogenics (NASDAQ:VBLT)‘s stock had its “buy” rating restated by investment analysts at Chardan Capital in a research note issued to investors on Thursday, AnalystRatings.com reports. They presently have a $3.25 price objective on the biopharmaceutical company’s stock. Chardan Capital’s price target would suggest a potential upside of 132.14% from the stock’s current price.

VBLT has been the subject of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective on shares of Vascular Biogenics in a research report on Friday, March 20th. Roth Capital reissued a “buy” rating on shares of Vascular Biogenics in a research report on Thursday, January 2nd. ValuEngine raised shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a research report on Thursday, February 6th. Finally, Zacks Investment Research cut shares of Vascular Biogenics from a “buy” rating to a “hold” rating in a research report on Wednesday, March 4th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $2.50.

Shares of NASDAQ:VBLT traded up $0.25 during mid-day trading on Thursday, reaching $1.40. 102,177 shares of the company were exchanged, compared to its average volume of 77,900. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.33 and a quick ratio of 4.33. The firm has a market cap of $51.67 million, a price-to-earnings ratio of -2.40 and a beta of 1.08. The firm’s 50-day simple moving average is $1.31 and its 200 day simple moving average is $1.29. Vascular Biogenics has a 1 year low of $0.90 and a 1 year high of $1.71.

Vascular Biogenics (NASDAQ:VBLT) last posted its quarterly earnings data on Thursday, March 19th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.03). The company had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.18 million. Vascular Biogenics had a negative return on equity of 45.23% and a negative net margin of 3,462.10%. On average, research analysts forecast that Vascular Biogenics will post -0.63 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in Vascular Biogenics stock. PVG Asset Management Corp purchased a new position in shares of Vascular Biogenics Ltd (NASDAQ:VBLT) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 40,030 shares of the biopharmaceutical company’s stock, valued at approximately $48,000. PVG Asset Management Corp owned approximately 0.11% of Vascular Biogenics at the end of the most recent reporting period. 4.22% of the stock is currently owned by hedge funds and other institutional investors.

About Vascular Biogenics

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.

See Also: What does it mean to hold a stock in street name?

Analyst Recommendations for Vascular Biogenics (NASDAQ:VBLT)

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.